
    
      This study is a Phase II, multicenter, randomized, double-blind, parallel-group,
      placebo-controlled for evaluation of the efficacy and safety of TAK-385 10, 20, and 40 mg
      (p.o.) following once daily administration for 12 weeks in women with uterine fibroids.
    
  